The trial of the Oxford/AstraZeneca vaccine in children has been paused while regulators investigate reports of a rare form of blood clot among adults.
The University of Oxford said no safety concerns have arisen from the trial itself.
But it is waiting for more information from the Medicines and Healthcare products Regulatory Agency (MHRA) before giving any more vaccinations.
Regulatory bodies from the UK, Europe and the World Health Organisation (WHO) are assessing data on the jab and a potential association with a rare form of blood clot.
The WHO and the European Medicines Agency (EMA) have confirmed they will publish findings later this week.
The MHRA has said it identified 30 cases of rare blood clot events out of 18.1 million doses of the jab administered up to and including March 24.
There have been seven deaths among the 30 cases.
But the regulator said the benefits of the vaccine in preventing coronavirus outweigh any risks and it urged the public to continue coming forward for the jab.
MHRA chief executive Dr June Raine said: “People should continue to get their vaccine when invited to do so.
“Our thorough and detailed review is ongoing into reports of very rare and specific types of blood clots with low platelets following the Covid-19 vaccine AstraZeneca.
“No decision has yet been made on any regulatory action.”
The 30 cases in the UK include 22 reports of CVST and eight of other thrombosis events with low platelets.
CVST clots stop blood draining from the brain properly.
House Rules
We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.
Read the rules hereLast Updated:
Report this comment Cancel